SEC Company Response from ACORDA THERAPEUTICS INC (CIK 0001008848) — Sep 16, 2020
ACORDA THERAPEUTICS INC (CIK 0001008848)
Date: Sept. 16, 2020 · CIK: 0001008848 · Accession: 0001193125-20-247216
AI Filing Summary & Sentiment
File numbers found in text: 333-248738
Letter
ACORDA THERAPEUTICS, INC.
420 SAW MILL RIVER ROAD
ARDSLEY, NY 10502
September 16, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Laura Crotty
Re: Acorda Therapeutics, Inc.
Registration Statement on Form S-3
Filed September 11, 2020
File No. 333-248738
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, Acorda Therapeutics, Inc. hereby requests that the effective date for above-referenced Registration Statement on Form S-3 be accelerated to 4:00 p.m., Eastern Time, on Thursday, September 17, 2020, or as soon as practicable thereafter.
Please contact Matthew C. Franker of Covington & Burling LLP at (202) 662-5895 or mfranker@cov.com with any questions you may have regarding this request. In addition, please notify Mr. Franker when this request for acceleration has been granted.
Respectfully,
Acorda Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP ACORDA THERAPEUTICS, INC. 420 SAW MILL RIVER ROAD ARDSLEY, NY 10502 September 16, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Laura Crotty Re: Acorda Therapeutics, Inc. Registration Statement on Form S-3 Filed September 11, 2020 File No. 333-248738 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, Acorda Therapeutics, Inc. hereby requests that the effective date for above-referenced Registration Statement on Form S-3 be accelerated to 4:00 p.m., Eastern Time, on Thursday, September 17, 2020, or as soon as practicable thereafter. Please contact Matthew C. Franker of Covington & Burling LLP at (202) 662-5895 or mfranker@cov.com with any questions you may have regarding this request. In addition, please notify Mr. Franker when this request for acceleration has been granted. Respectfully, Acorda Therapeutics, Inc. By: /s/ Andrew Mayer Name: Title: Andrew Mayer Deputy General Counsel and Corporate Secretary cc: Matthew C. Franker Covington & Burling LLP